Healthcare company Abbott has reported positive one-year outcomes from a real-world study of the use of its MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the US.
Designed to treat degenerative mitral regurgitation (DMR) patients, MitraClip performs transcatheter mitral valve repair by generating a vertical line of coaptation and forming a double-orifice valve.
The device enables real-time positioning and repositioning to optimise mitral regurgitation reduction.
The study assessed data of approximately 3,000 DMR patients who were high-risk for surgery, from the transcatheter valve therapy (TVT) registry.
The average age of the patients examined was 82 years.
Abbott structural heart business general manager Michael Dale said: "Abbott's goal is to improve health, and our MitraClip therapy provides a much-needed solution for gravely ill people who have very few options.
"The consistency in data across multiple trials reinforce the nearly immediate impact that MitraClip has on people's quality of life, allowing them to lead fuller, longer lives."
It was found that 92.8% of patients achieved post-procedural mitral regurgitation (MR) severity grade of less than or equal to 2, 80% did not require heart failure (HF) re-hospitalisation in the year after implantation and 85.9% were discharged to their homes after an average hospital stay of only two days.
The MitraClip is indicated for the percutaneous decrease of significant symptomatic mitral regurgitation due to primary abnormality of the mitral apparatus in patients who have been determined to be at prohibitive risk for mitral valve surgery.
The MitraClip delivery system is available in more than 50 countries, including the US.